Milestone Pharmaceuticals Inc
NASDAQ:MIST
Milestone Pharmaceuticals Inc
Research & Development
Milestone Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Milestone Pharmaceuticals Inc
NASDAQ:MIST
|
Research & Development
-$16.6m
|
CAGR 3-Years
26%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Research & Development
-$629m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-7%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Research & Development
-CA$478k
|
CAGR 3-Years
44%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Research & Development
-$4.4m
|
CAGR 3-Years
30%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Research & Development
-$105.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-152%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Research & Development
-CA$27.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-26%
|
|
Milestone Pharmaceuticals Inc
Glance View
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 29 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate is etripamil. The etripamil is a novel, potent and short-acting calcium channel blocker that has been designed rapid-onset nasal spray, which is self-administered by patients. The firm is developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF) and rapid ventricular rate, and other cardiovascular indications.
See Also
What is Milestone Pharmaceuticals Inc's Research & Development?
Research & Development
-16.6m
USD
Based on the financial report for Sep 30, 2025, Milestone Pharmaceuticals Inc's Research & Development amounts to -16.6m USD.
What is Milestone Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 5Y
17%
Over the last year, the Research & Development growth was -3%. The average annual Research & Development growth rates for Milestone Pharmaceuticals Inc have been 26% over the past three years , 17% over the past five years .
